Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
Vercauteren K, Brown RJ, Mesalam AA, Doerrbecker J, Bhuju S, Geffers R, Van Den Eede N, McClure CP, Troise F, Verhoye L, Baumert T, Farhoudi A, Cortese R, Ball JK, Leroux-Roels G, Pietschmann T, Nicosia A, Meuleman P.
Vercauteren K, et al. Among authors: cortese r.
Gut. 2016 Dec;65(12):2029-2034. doi: 10.1136/gutjnl-2014-309045. Epub 2015 Aug 25.
Gut. 2016.
PMID: 26306759